Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics

35

WATERTOWN, Mass.–(BUSINESS WIRE)–#Collaboration–Lyndra Therapeutics has announced a partnership with Gilead Sciences, Inc. to develop and commercialize ultra-long-acting oral HIV therapies. 

 

 

 

 

 

http://www.businesswire.com/news/home/20190708005768/en/Lyndra-Therapeutics-Gilead-Sciences-Collaborate-Development-Ultra-Long-Acting